X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
1
Enter email and you're done. No subscription, no credit card.
2
Search, tap and you're done. Over 3,400 medicines.
3
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Hydroxychloroquine was originally an antimalarial and is now a disease-modifying drug for systemic lupus erythematosus and rheumatoid arthritis. It is considered well tolerated, but it accumulates in body tissues over the years — including the retina. Because retinal damage causes no symptoms at first and cannot be cured, regular eye examinations are an integral part of long-term treatment.
See more detail.gif)
A daily reminder, your weekly schedule and the next retinal check in one place — free in the brite app.
| Property | Details |
|---|---|
| Active ingredient | Hydroxychloroquine (as hydroxychloroquine sulfate) |
| ATC code | P01BA02 |
| Drug class | 4-aminoquinoline, antimalarial; used in rheumatology as a disease-modifying drug |
| Dosage forms | Film-coated tablets (200 mg hydroxychloroquine sulfate) |
| Half-life | Very long: terminal half-life of 30 to 50 days according to the SmPC |
| Maximum daily dose | Maintenance dose in rheumatoid arthritis and lupus usually 200 to 400 mg according to the SmPC; the ophthalmology guideline recommends no more than 5 mg per kg of body weight per day |
| Onset of effect | Slow: success can be judged after 4 to 12 weeks at the earliest |
| Prescription status | Prescription-only medicine |
| Notable feature | Dose- and duration-dependent risk of incurable retinal damage — regular eye checks are needed; life-threatening in overdose, especially in children |
Hydroxychloroquine is a weak base. It accumulates in the acidic "recycling chambers" of cells, the lysosomes, and makes them less acidic. Immune cells need precisely these chambers to break down foreign components — or, in autoimmune diseases, the body's own — and present them to the immune system as an alarm signal. Hydroxychloroquine also dampens certain receptors that recognise fragments of genetic material and play a central role in lupus. The mechanism has not been fully clarified — the SmPC speaks cautiously of a possible dampening of immune reactions.¹
The result is a gentle dampening of the autoimmune reaction, not broad immunosuppression as with azathioprine. In systemic lupus erythematosus, the European guidelines therefore recommend hydroxychloroquine for everyone affected unless there is a reason against it: it reduces the number of flares and is associated with less organ damage and a better long-term outlook.² In rheumatoid arthritis its effect on its own is rather moderate; there it is usually combined with other disease-modifying drugs such as methotrexate.
The problems also follow from its chemistry. Hydroxychloroquine binds strongly to pigment (melanin). According to the SmPC, it reaches up to a thousand times its blood concentration in pigmented cells.¹ These include the pigment epithelium of the retina, the layer that supplies the light-sensing cells. Over the years, so much can build up there that the light-sensing cells are damaged — the core of this article. The enormous storage in tissue also explains the long half-life of 30 to 50 days: effects and side effects build up slowly and fade just as slowly after stopping.
The figures below describe what the SmPC and the guideline state. They are not a dosing instruction — your dose is set by the treating practice.
However, the guideline also stresses the other side: the necessary dose is set by the treating specialists, because too low a dose can lead to more frequent flares, especially in lupus.³ The upper limit from the ophthalmological point of view and the minimum effective dose from the rheumatological point of view therefore have to fit together.
Reminders with alternating doses — and your next eye appointment as well.
According to the SmPC, most side effects are dose-dependent. Overall, hydroxychloroquine is considered well tolerated — but you should still know about the rare risks, because they can be serious.¹
Low blood sugar: according to the SmPC, severe and sometimes life-threatening hypoglycaemia with loss of consciousness has occurred — in people both with and without diabetes medication. Heart: hydroxychloroquine can prolong the QT interval on the ECG and promote heart rhythm disorders; diseases of the heart muscle have been described during long-term treatment. Mental health: depression, agitation, psychosis and suicidal behaviour have been reported, typically in the first month of treatment and even without a psychiatric history. Muscles and nerves: progressive weakness, especially of the muscles close to the trunk, can indicate a myopathy. Skin: very rarely, severe skin reactions with blisters and fever occur.¹
Retinal damage caused by hydroxychloroquine (retinopathy) affects the light-sensing cells and the layer that supplies them. Once cells have been lost, it is irreversible, there is no treatment — and in advanced stages it continues to progress for years, even after stopping. The aim of screening is therefore not to prevent retinopathy, but to detect it so early that stopping in time preserves your sight.³
According to the S1 guideline of the German Ophthalmological Society, the Professional Association of Ophthalmologists in Germany and the Retinological Society, at the recommended dose the risk is below one per cent after five years, in the range of a few per cent after ten years and around 20 per cent after 20 years.³ So the risk is very small at first and grows markedly over the years. These figures are based on large analyses that also underpin the recommendations of the American Academy of Ophthalmology.⁴
| When | What is examined | Why |
|---|---|---|
| In the first months of treatment | Visual acuity, visual field, back of the eye (fundus), OCT | Baseline findings; detecting and documenting any existing damage |
| Years 1 to 5 without risk factors | No routine screening appointments needed; immediately if vision problems occur | The risk is very low in this phase |
| Years 1 to 5 with risk factors | Annually, as for the baseline examination | Early detection when the risk is increased |
| From the 5th year of treatment | Annually, as for the baseline examination | Early detection before symptoms appear |
The most important method is optical coherence tomography (OCT), a cross-sectional scan of the retina. Fundus autofluorescence and the multifocal electroretinogram are equally suitable. According to the guideline, a suspicion should be confirmed with a second of these methods before stopping is advised. In people of Asian or African origin, the damage often starts further out and has to be looked for with a wider field of view.³
Symptoms appear only late. In people of European origin, the damage usually starts in a ring around the point of sharpest vision: letters "go missing" when you read, even though your visual acuity is normal. Reading problems like these or new visual disturbances are a reason for a prompt appointment, not something to leave until the next routine check. How medicines in general can affect the eyes is explained in the guide medications and eyes.
Existing retinal diseases, such as macular degeneration, are a special case. The SmPC lists pre-existing retinopathy or maculopathy as a contraindication, whereas the guideline does not regard it as an obstacle in principle, because the typical changes can usually be told apart well.¹,³ Here the eye practice and the rheumatology practice decide together.
Hydroxychloroquine has few interactions, but some weighty ones. Many involve medicines prescribed by a different practice — an antibiotic or an antidepressant, for example.¹
| Combination | Consequence | What to do |
|---|---|---|
| Tamoxifen | Both can damage the retina | Not recommended according to the SmPC; if unavoidable, annual screening from the start |
| QT-prolonging drugs, e.g. citalopram, azithromycin, fluoroquinolones, antipsychotics, amiodarone | Increased risk of dangerous heart rhythm disorders | Inform the prescribing practice, ECG if needed; avoid the combination where possible |
| Insulin and other blood sugar-lowering drugs | Stronger lowering of blood sugar, up to severe hypoglycaemia | Measure blood sugar more often; reduce the dose of diabetes medicines if needed |
| Magnesium-containing antacids, kaolin | Reduced absorption of hydroxychloroquine | At least 2 hours apart |
| Digoxin, dabigatran, ciclosporin | Higher levels of these drugs possible | Watch for side effects, check levels if needed |
| Methotrexate | The effect of methotrexate can be increased | A common, intended combination in rheumatoid arthritis — with the usual checks |
| Antiepileptics, mefloquine, bupropion | The seizure threshold falls; the effect of antiepileptics can wane | Close medical supervision in epilepsy |
| Rifampicin, carbamazepine, St John's wort | The effect of hydroxychloroquine can wane | Monitor effectiveness, inform the practice |
| Alcohol | Larger amounts strain the liver; increased drowsiness | Restraint; see medications and alcohol |
The tamoxifen combination deserves particular attention because it arises across specialist boundaries: a woman with lupus or rheumatoid arthritis develops breast cancer, the oncology practice prescribes tamoxifen — and the retinal risk rises without the eye practice ever finding out. The QT interval is similarly invisible: each drug on its own is unproblematic, but together with an antibiotic from the out-of-hours practice it can become critical. This is exactly where the brite interaction check helps: it checks every new prescription against your complete list. More background in the guide drug interactions.
Besides the eyes, according to the SmPC and rheumatology therapy information, further checks are part of long-term treatment. The specific plan is set by the treating practice.¹,⁵
| Check | Why | How often (for orientation) |
|---|---|---|
| Blood count | Detecting rare changes in the blood count early | According to the SmPC, before starting long-term treatment and at two-monthly intervals |
| Kidney values (creatinine, eGFR) | Declining kidney function increases the retinal risk | Regularly, especially in older age and in lupus with kidney involvement |
| Liver values | Rare liver damage | Immediately if symptoms occur, otherwise according to the practice's plan |
| ECG | QT prolongation, heart muscle disease | In heart disease and with QT-prolonging concomitant medicines |
| Blood sugar | Risk of hypoglycaemia | More closely at the start in people with diabetes |
| Muscle strength and reflexes | Rare myopathy | Regularly during long-term treatment according to the SmPC |
Here the SmPC and specialist advice diverge. For rheumatoid arthritis and lupus, the SmPC advises avoiding hydroxychloroquine in pregnancy unless the benefit outweighs the risk, and rules out breastfeeding because the drug could accumulate in the infant.¹ Embryotox has extensive experience and considers continuing or even starting it at the usual dose to be justifiable; in lupus, continuing it during pregnancy is expressly recommended in order to reduce disease-related complications. According to Embryotox, healthy babies born at term may be breastfed at the usual dose, provided paediatric follow-up is ensured.⁶ So if you become pregnant, do not stop hydroxychloroquine on your own, but talk to your practice straight away; more in the guide medications during pregnancy.
There is no withdrawal syndrome with hydroxychloroquine. The risk lies in the underlying disease: in lupus, according to the guideline, too low a dose or stopping can lead to more frequent flares.³ Because of the long half-life, a flare often comes only weeks to months later — and is then no longer linked to stopping. If retinopathy has been confirmed, on the other hand, the drug is stopped promptly and treatment is switched to something else. More on the planned approach under stopping medications.
Because "seeing normally" means nothing where this side effect is concerned. The damage starts outside the point of sharpest vision and goes unnoticed for a long time; by the time you notice it, it usually can no longer be reversed. OCT finds it years earlier. It is annoying that the examination is currently not covered by statutory health insurance — but the bill has to be weighed against an irreversible reading problem. From the fifth year onwards, it is one appointment a year.
This happens because different ways of calculating are in circulation: the SmPC works with ideal body weight and a higher upper limit, the ophthalmology guideline with 5 mg per kilogram of body weight. On top of that come out-of-date weight entries in your records. Ask both practices to coordinate directly, and bring your current weight and the exact weekly dose with you. Do not reduce the dose on your own — in lupus, too low a dose can trigger flares.
Stomach complaints are the most common side effect and often improve after a few weeks. Taking it with food and, after consultation, a temporarily lower dose can help. Tell your practice before you stop: because of the long half-life, quietly abandoning treatment is often only noticed at the next flare.
The interaction check tests new prescriptions against your whole list.
Dose reminders, eye and lab findings over time and an interaction check in one place. Free.
Create medication plan